tometer and the number of viable cells scored on the basis of their ability to exclude eosin. In some expemments, cells were exposed to AKR mouse antl-Thy 1.2 serum (from Dr J B Smith) and complement; control cell suspensions received the same treatment except that AKR normal serum was substituted for AKR antl-Thy 1.2 serum This was done as described previously (7) All cell preparations were made up in Hanks' balanced salt solution containing 2% fetal calf serum (Flow Laboratories, Inc, Rockvllle, Md.) and were rejected intrapemtoneally m 0.5-1.0-ml vol per mouse
The sublethal X-irradiation of BALB/c recipients (550 R) was carried out 1 day before cell transfer at the following conditions' 190 kV'15 mA; filtration 1 mm Al and 0.5 mm Cu; dose rate 40-45 R mln-'. At various times after cell transfer, recipients were bled and their sera reacted with BALB/c antl-G 2 m mlcro-Ouchterlony plates to test for the presence of the G 2 marker
Results and Discussion G2-specific immunity of normal mice was first inferred from the relative inability of CBPC 101 to grow in BALB/c and in C.AL-20 mice. As shown in Table I None of the mice in groups A-C of Table I produced detectable anti-G 2. This suggested to us that the tumor elicited a cellular immune response in which allotype-specific T cells were the mediators. To test this idea, we carried out the experiments shown in Table II . Here, we used sublethally X-irradiated (550 R) BALB/c mice as recipients of various cell mixtures containing CBPC 101 cells. X-irradiation before the injection of CBPC 101 cells enabled the tumor to grow as indicated by the production of G 2 (group A). Further, all of these recipients died of the tumor within 5 wk. However, as indicated in group B, CBPC 101 cells would not grow and produce G 2 when cotransferred with BALB/c spleen cells taken from donors that received CBPC 101 cells 15 wk earlier (from group A of Table I ). When the same spleen cell suspension was treated with AKR anti-Thy 1.2 serum and complement (instead of with normal AKR serum and complement as in group B), the tumor did grow (group B'). Thus, it seems clear that spleen cells from CBPC 101-challenged mice contain T cells that can prevent the growth of the tumor. It is important to note that we did not obtain any evidence for suppressed tumor cells in the spleens of CBPC 101-challenged mice as the transfer of anti-Thy 1.2-treated spleen cells alone did not result in any G 2 production or obvious tumor growth (group B"). Presumably, suppressed tumor cells would have become active in the absence of suppressor T cells. Thus, the likely fate of CBPC 101 cells m BALB/c mice is death from lysis or from a T-cell factor.
Table II demonstrates further that spleen cells of CBPC 101-challenged BALB/c mice are also able to prevent the G ' 2 production of normal C.B-17 B cells. Table I ) Spleen cells in groups B' and B ~ were treated with AKR antl-Thy i 2 and complement before being transferred to Xirra&ated BALB/c reclplents, the spleen cells of group B were treated m the same manner except that normal AKR mouse serum was substituted for AKR antl-Thy i 2 Although not shown, the reclpmnts of group C still continued to produce the IgG~ anotype (F ~) of C B-17 mice 7 wk after cell transfer as evldent from reacting their sera with anti-C~F' sera (7) This is shown in group C. But as with G2-suppressed C.B-17 mice in earlier experiments (7), the C.B-17 B cells in group C did not stop producing their IgG1 allotype (F s) (see footnote of Table II Immune spleen cells were taken from mice that were producing anh-G m response to pumfied Fc fragments of C57BL/6 7S Ig (7) and from mice that were producing anh-G 4 (antl-C AL-20 IgG2a) The CBPC 101 cells m groups A-C were treated with AKR anhThy 1 2 serum and complement before being transferred into X-irradiated BALB/c reclpmnts where CBPC 101 cells would not grow in the presence of BALB/c spleen cells containing G z Tcs that had been primed against purified Fc fragments of C57BL 7S Ig, whereas the tumor did grow in the presence of BALB/c spleen cells taken from mice immune to the IgG2a allotype of C.AL-20 mice (G4).
Consistent with the results of Table I, Table III The question prompted by the above results is how can spleen cells of normal BALB/c mice mount so rapid and effective a response against tumor cells that bear an allotype antigen that these mice have never seen experimentally? To account for this, we suggest that not only is the G 2 marker very antigenic, but that a considerable number of G 2 Tcs cells or their precursors are present in normal BALB/c mice. In addition to the suggested presence of G 2 Tcs cells, we have unpublished evidence that BALB/c mice also contain Tcs cells directed against IgG2a allotype determinants (G 4) of C.AL-20 mice. This raises an interesting possibility that different mouse strains may contain different allotypespecific Tcs cells, and that the stimulus for generating such Tcs cells may be provided by allotype antigens normally undetectable (hidden allotypes). Irregularities or specific stress of this regulatory system could result in detectable production of hidden allotypes. In fact, similar to our earlier findings (9), we can now show with radioimmune techniques the transient appearance of allotypes indistinguishable from those of BALB/c IgGl and IgG2a in C.B-17 mice. 1 AddiBosma, M, and C L De Wltt. Manuscript in preparation tional evidence for the regulatory control of allotype production is the observed nonallelic behavior of Ig allotypes in rabbits (10, 11) . Also, the production of unexpected allotypes by normal (and neoplastic, 12) human lymphocytes has been reported (13, 14) ; however, several laboratories (15, 16) have not been able to confirm these observations (13, 14) . Structural evidence consistent with the idea of regulatory control of allotype production is also available. Most constant region (C) allotypes of human heavy (H) chains correspond to multiple antigenic differences (16) , some of which (in the case of IgG3) have been localized to different CH regions (17) . Moreover, constant region allotypes of light chains (CL) in rat (18) and in rabbit (19, 20) , as well as rabbit allotypes on H chain variable regions (VH) (16), correlate not with a few but with many amino acid differences. Evolutionary considerations of such "complex" allotypes have led some (18) (19) (20) (21) to suggest that these allelic differences may reflect the products of different linked genes and that the basis for the genetic polymorphism is in the control of such genes.
The advantage of regulating IgG production by allotype-specific Tcs cells is not clear although one could suppose in the above context that hidden mouse allotypes reflect CH allotype genes that are associated with different sets of VH genes; this, then, would suggest a way of controlling the expression of select sets of V~ genes. Summary BALB/c T cells, which can prevent normal C57BL IgG~ allotype (G a) production of Ig-congenic partner mice (C.B mice), are shown capable of preventing the growth and G a production ofa C.B plasmacytoma (CBPC 101). Such cytotoxic or suppressor T cells are clearly allotype-specific (G 2 Tcs cells). And since CBPC 101 B cells do not require specific helper T cells in order to grow, we infer that G2-bearing B cells (normal or neoplastic) must be the direct target of G a Tcs cells. This mode of T cell prevention of allotype production contrasts that reported for suppressor T cells in (BALB/c × SJL)FI mice.
